Canada Newborn Screening Market Size & Outlook, 2023-2030
Canada newborn screening market, 2018-2030 (US$M)
Related Markets
Canada newborn screening market highlights
- The Canada newborn screening market generated a revenue of USD 16.8 million in 2023 and is expected to reach USD 28.0 million by 2030.
- The Canada market is expected to grow at a CAGR of 7.6% from 2024 to 2030.
- In terms of segment, tandem mass spectrometry was the largest revenue generating technology in 2023.
- Tandem Mass Spectrometry is the most lucrative technology segment registering the fastest growth during the forecast period.
Newborn screening market data book summary
| Market revenue in 2023 | USD 16.8 million |
| Market revenue in 2030 | USD 28.0 million |
| Growth rate | 7.6% (CAGR from 2023 to 2030) |
| Largest segment | Tandem mass spectrometry |
| Fastest growing segment | Tandem Mass Spectrometry |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tandem Mass Spectrometry, Pulse Oximetry, Enzyme-based Assay, DNA Assays, Electrophoresis |
| Key market players worldwide | Bio-Rad Laboratories Inc, Agilent Technologies, Agilent Technologies Inc, Covidien, Masimo Corp, Waters Corp, Natus Medical, GE HealthCare Technologies Inc Common Stock, PerkinElmer, Danaher Corp |
Other key industry trends
- In terms of revenue, Canada accounted for 2.1% of the global newborn screening market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. newborn screening market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 28.0 million by 2030.
Tandem mass spectrometry was the largest segment with a revenue share of 24.4% in 2023. Horizon Databook has segmented the Canada newborn screening market based on tandem mass spectrometry, pulse oximetry, enzyme-based assay, dna assays, electrophoresis covering the revenue growth of each sub-segment from 2018 to 2030.
Unlike the extreme awareness levels witnessed in the U.S., Canada is still lagging in its efforts towards newborn screening program. Officially, Canada has no national standards set for screening of neonates and uses the ones established by the U.S. Mandated screening is applicable on only two conditions of those listed in the RUSP, which are congenital hypothyroidism and phenylketonuria.
However, in an attempt to change the scenario, Canadian Newborn and Child Screening Symposium held in May 2015 at Ontario highlighted the upcoming plans for the next five years. A few pointers of the plan are increasing involvement in innovation for newborn screening, collaborations, and tie-ups between industry representatives, clinicians, and market players and formation of uniform policies and standards.
Assisted regional growth can be witnessed over the next few years due to the market player PerkinElmer, which has commercially introduced the product range, EnLite, for Severe Combined Immunodeficiency (SCID) in December 2014
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Newborn Screening Market Scope
Newborn Screening Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada newborn screening market size, by technology, 2018-2030 (US$M)
Canada Newborn Screening Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
